And relative to the program rollout, they really vary in timeframe. Probably the area that we've spent the most money on doesn't necessarily have a current driver, but we know, long-term, the drivers are there. So for example, to extend our TIFI chemical injection strategy to applications other than filing and sliding, and then use it for removal of flukes. For example, we've successfully demonstrated that with SO3 in Mexico and elsewhere. We believe we have opportunities to mitigate SO2, but there's not a current driver for that. That will be a long-term program at which we'll be ready to participate. On the other hand, there are drivers for acid gases, particularly hydrogen chloride. I mentioned earlier that the Boiler MACT rule that was finalized at year-end 2012 requires compliance. We're also seeing the opportunity to create economic chemical programs that aren't just going to be utilized because there's a regulatory requirement. So if you can remove corrosive acid gases to avoid either the deterioration of, or the expenditure of very large capital expenditures on the back end, that's valuable. So if anything, I would think our program for mitigating the generation of hydrogen chloride as corrosive gases has the earliest opportunities. When are those? Probably, at best, the rollout is late this year, could be 2014. But we have a program of -- that's really diversified projects that, over time, will yield these new opportunities. We've also been conducting tests to enhance our traditional SNCR and NOx reduction capabilities. And if you think about that, there's 2 benefits: One, you can go back to previous installations and improve their performance without applying a different technology; two, you can make your technology more competitive versus those that require greater capital expenditures and enjoy a more competitive position. So enhancements to existing capabilities like SNCR, new chemical programs that either provide an economic benefit or meet a regulatory requirement that utilize our FUEL CHEM business model that, therefore, give us recurring revenues are the principal objectives of our R&D program. So like any development, if you don't make the investments, you're not competitively positioned to enjoy the benefits. So that's why we consciously began that some time ago and will continue. I think our guidance for you is to look to us to spend about 3% of our revenues overall. Every one of these projects has a keen eye towards meriting investment. And many of them require investments related to commercial testing before they can be marketed. So we're on top of an interesting portfolio of opportunities.